19.73

2.86% -0.58

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $19.73, with a volume of 1.05M. It is down -2.86% in the last 24 hours and down -22.41% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Previous Close:

$20.31

Open:

$20.22

24h Volume:

1.05M

Relative Volume:

0.70

Market Cap:

$3.40B

Revenue:

$1.10B

Net Income/Loss:

$375.65M

P/E Ratio:

8.9833

EPS:

2.1963

Net Cash Flow:

$113.59M

1W Performance:

+3.19%

1M Performance:

-22.41%

6M Performance:

-10.76%

1Y Performance:

-9.20%

1-Day Range:

$19.58

$20.25

1-Week Range:

$19.11

$20.57

52-Week Range:

$18.39

$30.96

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

798

Twitter

@acadiapharma

Next Earnings Date

2026-11-04

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD Acadia Pharmaceuticals Inc	19.73	3.40B	1.10B	375.65M	113.59M	2.1963
VRTX Vertex Pharmaceuticals Inc	523.93	132.80B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.02	82.88B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	200.10	79.89B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	873.71	54.94B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	377.63	42.72B	5.76B	514.49M	1.10B	4.4813

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-26	Downgrade	UBS	Buy → Neutral
Mar-25-26	Upgrade	BofA Securities	Neutral → Buy
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-23-26	Upgrade	Mizuho	Neutral → Outperform
Oct-21-25	Initiated	Citigroup	Buy
May-21-25	Upgrade	Deutsche Bank	Hold → Buy
Feb-11-25	Initiated	Deutsche Bank	Hold
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

Oct 22, 2026

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Oct 22, 2026

Oct 21, 2026

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research

Oct 21, 2026

Oct 20, 2026

Needham keeps USD 35.00 target for ACADIA Pharmaceuticals stock - ad-hoc-news.de

Oct 20, 2026

FDA Approval for DAYBUE STIX issued to ACADIA PHARMS INC - Quantisnow

Oct 20, 2026

Oct 17, 2026

ACADIA Pharmaceuticals stock has a USD 31.34 consensus target from 18 analysts - ad-hoc-news.de

Oct 17, 2026

Oct 16, 2026